FDA 483 - Baxter Corporation - January 31, 2025

Baxter Corporation, a parenteral drug manufacturer in Alliston, was cited for significant deficiencies during an FDA inspection. Observations included inadequate investigations into unexplained discrepancies and packaging failures, issues with manufacturing process validation and container integrity, and failures in preventing contamination and conducting proper component identification testing. These issues indicate a lack of robust quality control and investigation practices.